uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England..
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England..
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England..
Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England..
Show others and affiliations
2016 (English)In: Carcinogenesis, ISSN 0143-3334, E-ISSN 1460-2180, Vol. 37, no 9, 852-857 p.Article in journal (Refereed) Published
Abstract [en]

Single nucleotide polymorphisms (SNPs) in microRNA genes have been associated with colorectal cancer (CRC) risk, survival and response to treatment. Conflicting results are available on the association between rs4919510, a SNP in mature miR-608 and clinical outcome in CRC. Here, we analyzed the association between rs4919510 and benefit from perioperative treatment in a randomised phase II trial of neoadjuvant Capecitabine and Oxaliplatin (CAPOX) followed by chemo-radiotherapy, surgery and adjuvant CAPOX +/- Cetuximab in high-risk locally advanced rectal cancer (LARC). A total of 155/164 (94.5%) patients were assessable. 95 (61.3%) were homozygous for CC, 55 (35.5%) heterozygous (CG) and 5 (3.2%) homozygous for GG. Median follow-up was 64.9 months. In the CAPOX arm the 5-year progression-free survival (PFS) and overall survival (OS) rates were 54.6% and 60.7% for CC and 82.0% and 82.1% for CG/GG, respectively (HR PFS 0.13, 95% CI: 0.12-0.83, P = 0.02; HR OS 0.38, 95% CI: 0.14-1.01, P = 0.05). In the CAPOX-C arm PFS and OS were 73.2 and 82.2%, respectively for CC carriers and 64.6 and 73.1% for CG/GG carriers (HR PFS 1.38, 95% CI: 0.61-3.13, P = 0.44; HR OS 1.34, 95% CI: 0.52-3.48, P = 0.55). An interaction was found between study treatment and rs4919510 genotype for both PFS (P = 0.02) and OS (P = 0.07). This is the first study investigating rs4919510 in LARC. The CC genotype appeared to be associated with worse prognosis compared to the CG/GG genotype in patients treated with chemotherapy and chemo-radiotherapy alone. Addition of Cetuximab to chemotherapy and chemo-radiotherapy in CC carriers appeared to improve clinical outcome.

Place, publisher, year, edition, pages
2016. Vol. 37, no 9, 852-857 p.
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-307293DOI: 10.1093/carcin/bgw073ISI: 000385133900003PubMedID: 27381831OAI: oai:DiVA.org:uu-307293DiVA: diva2:1046043
Available from: 2016-11-11 Created: 2016-11-11 Last updated: 2016-11-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Glimelius, Bengt
By organisation
Experimental and Clinical Oncology
In the same journal
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 61 hits
ReferencesLink to record
Permanent link

Direct link